首页> 外文OA文献 >An open-label, single-arm, phase 1 study to assess biomarker effects, efficacy and safety of ofatumumab in patients with refractory chronic lymphocytic leukemia

【2h】

An open-label, single-arm, phase 1 study to assess biomarker effects, efficacy and safety of ofatumumab in patients with refractory chronic lymphocytic leukemia

机译：开放标签，单臂，第1期，用于评估难治性慢性淋巴细胞白血病患者患者的生物标志物效应，疗效和安全性

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

著录项
引文网络
相似文献
相关主题

著录项

作者
William Nigel Patton; Robert Lindeman; Andrew C. Butler; Thomas J. Kipps; Roxanne C. Jewell; Kevin H. Laubscher; Yan Yan Zhou; Eric Lewis; Donna Sedoti; Philip Witman; Lei Fang; Geoffrey Chan;
展开▼
作者单位

展开▼
年度 2015
总页数
原文格式 PDF
正文语种
中图分类

相似文献

外文文献
中文文献
专利

1. An open-label, single-arm, phase 1 study to assess biomarker effects, efficacy and safety of ofatumumab in patients with refractory chronic lymphocytic leukemia [J] . Patton William Nigel, Lindeman Robert, Butler Andrew C., Leukemia and lymphoma . 2015,第10期

机译：一项开放性单臂1期研究，评估难治性慢性淋巴细胞性白血病患者中ofatumumab的生物标志物作用，疗效和安全性
2. Safety and efficacy of ofatumumab, a fully human monoclonal anti-CD20 antibody, in patients with relapsed or refractory B-cell chronic lymphocytic leukemia: a phase 1-2 study. [J] . Coiffier B, Lepretre S, Pedersen LM, Blood: The Journal of the American Society of Hematology . 2008,第3期

机译：Ofatumumab（一种完全人类单克隆抗CD20抗体）在复发或难治性B细胞慢性淋巴细胞性白血病患者中的安全性和有效性：1-2期研究。
3. Five-Year Follow-up of Safety and Efficacy of a Phase III Randomized Trial of Ofatumumab Therapy Versus Physicians' Choice in Patients with Bulky Fludarabine Refractory Chronic Lymphocytic Leukemia [J] . Miklos Udvardy, Strugov Vladimir, Lewerin Catharina, Blood: The Journal of the American Society of Hematology . 2018,第NovaelaTreatmentAppr期

机译：III期患者对甘露出急性慢性淋巴细胞白血病患者III期随机试验的五年随机试验的安全性和疗效。
4. Histones as Biomarkers in Chronic Lymphocytic Leukemia [C] . Xiaodan Su, David E. Lucas, Liwen Zhang, ASMS Conference on Mass Spectrometry and Allied Topics . 2006

机译：组蛋白作为慢性淋巴细胞白血病的生物标志物
5. Safety and Efficacy of the Immunomodulatory Drug (IMiD) Lenalidomide in Patients with Lymphoma: Development of RU051417I - Phase I/II Open-Label Study of R-ICE (Rituximab-Ifosfamide-Carboplatin-Etoposide) with Lenalidomide [R2-ICE] in Patients with First-Relapse/Primary Refractory Diffuse Large B-Cell Lymphoma (DLBCL). [D] . Kasi, Pashtoon Murtaza. 2018

机译：免疫调节药物来那度胺在淋巴瘤患者中的安全性和有效性：RU051417I-R-ICE（利妥昔单抗-异环磷酰胺-卡铂-依托泊苷）与来那度胺[R2-ICE]的I / II期开放标签研究的进展初次复发/原发性难治性弥漫性大B细胞淋巴瘤（DLBCL）。
6. An Open-Label Single-Arm Phase 1 Study to Assess Biomarker Effects Efficacy and Safety of Ofatumumab in Patients With Refractory Chronic Lymphocytic Leukemia [O] . William Nigel Patton, Robert Lindeman, Andrew C. Butler, -1

机译：一项开放标签单臂的1期研究以评估Ofatumumab对难治性慢性淋巴细胞白血病患者的生物标志物作用疗效和安全性
7. Safety and efficacy of ofatumumab, a fully human monoclonal anti-CD20 antibody, in patients with relapsed or refractory B-cell chronic lymphocytic leukemia:a phase 1-2 study [O] . Coiffier Bertrand, Lepretre Stéphane, Pedersen Lars Møller, 2008

机译：完全人类单克隆抗CD20抗体ofatumumab在复发或难治性B细胞慢性淋巴细胞性白血病患者中的安全性和有效性：1-2期研究

An open-label, single-arm, phase 1 study to assess biomarker effects, efficacy and safety of ofatumumab in patients with refractory chronic lymphocytic leukemia

著录项

引文网络

相似文献

相关主题

期刊订阅